Mammary Cell News 11.35 September 12, 2019 | |
| |
TOP STORYScientists demonstrated that COX7RP overexpression in breast and endometrial cancer cells promoted in vitro and in vivo growth, stabilized mitochondrial supercomplex assembly even in hypoxic states, and increased hypoxia tolerance. Metabolomic analyses revealed that COX7RP overexpression modulated the metabolic profile of cancer cells, particularly the steady-state levels of tricarboxylic acid cycle intermediates. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers demonstrated a correlation between intracellular redox potential and the concentrations of miRNAa involved in the cells’ response to changes in oxygen pressure. The correlations were established using surprisal analysis. [Proc Natl Acad Sci USA] Abstract Investigators designed a pH-sensitive nanotherapeutic system based on propylene glycol alginate sodium sulfate (PSS), a marine sulfated polysaccharide that possesses anti-platelet aggregation activity and has been used as a heparinoid drug in China. A facile one-pot nanoprecipitation method was used to prepare this nanotherapeutic system named as PSS@DC nanoparticles, in which DOX and CXB were complexed to form hydrophobic nanocores and PPS coated these nanocores through conjugation with DOX via a highly acid-labile benzoic-imine linker. [Acta Biomater] Full Article | Graphical Abstract The authors showed that Tam5R cells exhibited a significant decrease in mitochondrial respiration, low abundance of assembled mitochondrial respiratory supercomplexes, a more fragmented mitochondrial network connected with DRP1 Ser637 phosphorylation, higher glycolysis and sensitivity to 2-deoxyglucose. [Free Radic Biol Med] Full Article | Graphical Abstract Researchers found that protease nexin-1 (PN-1) was up-regulated in breast cancer, which promoted cell invasion, migration and stemness. Furthermore, by using specific inhibitors, they discovered that epidermal growth factor (EGF) up-regulated PN-1 in breast cancer cells through cascade activation of epidermal growth factor receptor to the activation of protein kinase Cδ, mitogen-activated protein kinase and extracellular signal-related kinase, which finally led to the up-regulation of early growth response protein 1. [Cell Death Dis] Full Article Investigators report that breast cancer (BrCa) cells expressing mutp53 were more resistant to adriamycin than cells with wild-type p53. The DNA repair protein Fanconi anemia complementation group F protein and the translesion synthesis DNA polymerase REV1 protein was frequently abundant in the context of mutant p53 of BrCa. [Cell Death Dis] Full Article Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy Scientists report the development and characterization of human/rat-specific JAG1-neutralizing monoclonal antibodies. Epitope mapping identified their binding to the Notch receptor interaction site within the JAG1 Delta/Serrate/Lag2 domain, where E228D substitution prevented effective binding to the murine Jag1 orthologue. [Mol Cancer Ther] Abstract | Full Article miRNA-Dependent Regulation of STIM1 Expression in Breast Cancer The authors showed that STIM1 expression was regulated post-transcriptionally by the miRNA machinery and identified miR-223 and miR-0150 as regulators of STIM1 expression in the luminal non-aggressive MCF7 breast cancer cell line. In contrast, STIM1 expression in the more aggressive basal triple-negative MDA-MB-231 cell line was not significantly modulated by a single miRNA species but was rather upregulated due to inhibition of the miRNA machinery through downregulation of Ago2. [Sci Rep] Full Article Overexpression and Alternative Splicing of NF-YA in Breast Cancer Researchers focused on breast carcinomas, and analyzed RNA-Seq datasets of TCGA and 54 BRCA cell lines at gene and isoforms level. They partitioned all tumors in the four major subclasses. NF-YA, but not histone-fold subunits NF-YB/NF-YC, was globally overexpressed, correlating with the proliferative Ki67 marker and a common set of 840 genes, with cell-cycle, metabolism GO terms. [Sci Rep] Full Article Investigators showed that treatment with ouabain caused simultaneous activation of AMPK and Src signaling pathways in human lung cancer A549 cells and human breast cancer MCF7 cells. Co-treatment with AMPK inhibitor compound C or siRNA greatly abrogated ouabain-induced Src activation, whereas co-treatment with Src inhibitor PP2 had little effect on ouabain-induced AMPK activity, suggesting that AMPK served as an upstream regulator of the Src signaling pathway. [Acta Pharmacol Sin] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSCancer-Associated Adipocytes: Key Players in Breast Cancer Progression Scientists focus on the potential mechanisms involved with special attention to the adipocyte-cancer cell circle in breast cancer. They envisage that besides having a direct impact on tumor cells, cancer-associated adipocytes systemically preconditions the tumor microenvironment by favoring anti-tumor immunity. [J Hematol Oncol] Full Article Panoptic View of Prognostic Models for Personalized Breast Cancer Management The authors summarize the prognostic and predictive insights provided by commercially available gene expression-based tests and other multivariate or clinical -omics-based prognostic/predictive models currently under development, and proposes a more inclusive multiplatform approach to tackling the challenging heterogeneity of breast cancer to individualize its management. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSCyclacel Pharmaceuticals, Inc. announced treatment of the first patient with an oral formulation of CYC065, a CDK2/9 inhibitor, in part 3 of a Phase I study which is evaluating single agent CYC065 in patients with advanced solid cancers. Parts 1 and 2 of the study are evaluating CYC065 administered as an intravenous infusion. [Cyclacel Pharmaceuticals, Inc.] Press Release Daiichi Sankyo Company, Limited announced the submission of a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for the use of [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate, for the treatment of patients with HER2 positive metastatic breast cancer. [Daiichi Sankyo Company] Press Release Laskers Go to Immunologists, Developers of Breast Cancer Therapy The 2019 Lasker-DeBakey Clinical Medical Research Award goes to H. Michael Shepard, formerly of Genentech, Dennis Slamon of the University of California, Los Angeles, and Axel Ullrich of the Max Planck Institute of Biochemistry and formerly of Genentech for the development of a monoclonal antibody therapy called Herceptin that has saved the lives of countless women with breast cancer. [TheScientist] Press Release | |
| |
POLICY NEWSClubby and ‘Disturbing’ Citation Behavior by Researchers in Italy Has Surged The rate at which scientists in Italy cite themselves and their compatriots is rising faster than in ten other developed countries, according to a new study. The surge in Italy’s clubby citation behavior is likely the result of a 2010 law requiring productivity standards for academic recruitment or promotion, the study authors say. [ScienceInsider] Editorial EU Research Commissioner Named, but Lacks ‘Research’ in Her Title Mariya Gabriel, a conservative politician from Bulgaria, is slated to become the next European research chief- although her job title, unlike that of her predecessors, doesn’t include the words “research” or “science.” Some researchers and science policy experts worry the new job title could signal a reduced standing for science within von der Leyen’s proposed executive branch for the European Union, made up of 26 commissioners. [ScienceMagazine] Editorial US EPA to Eliminate All Mammal Testing by 2035 The US Environmental Protection Agency (EPA) in Washington, DC, announced September 10th that it will stop conducting or funding studies on mammals by 2035. The move, which is already eliciting strong reactions from groups supporting or opposing experiments on animals, makes EPA the first federal agency to put a hard deadline on phasing out animal research. [Science Magazine] Editorial
| |
EVENTSNEW Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESProject Scientist – Breast and Hematological Tumors (Cedars-Sinai) Scientific Communications Coordinator (STEMCELL Technologies Inc.) Postdoctoral Fellow – Breast and Prostate Cancer (Mayo Clinic Comprehensive Cancer Center) Research Assistant – Endocrinology in Breast Cancer and Diabetes (Northwell Health) Bioinformatician – Breast Cancer (Royal College of Surgeons in Ireland) Postdoctoral Fellow – T-Cell Immunotherapy in Cancers (Memorial Sloan Kettering Cancer Center) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|